Envista Holdings Corporation
NYSE•NVST
執行長: Mr. Stephen Keller
板塊: Healthcare
行業: Medical - Equipment & Services
上市日期: 2019-09-18
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
聯絡資訊
Building E, 200 South Kraemer Boulevard, Brea, CA, 92821-6208, United States
714-817-7000
市值
$4.41B
本益比 (TTM)
94.5
57.7
股息率
--
52周最高
$30.42
52周最低
$14.72
52周範圍
排名40Top 42.0%
4.1
F-Score
改良版 Piotroski 分析
基於 9 年期基本面
一般 • 4.1 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2017-2025
財務儀表板
Q4 2025 數據
營業收入
$750.60M+0.00%
近4季度走勢
每股收益
$0.20+0.00%
近4季度走勢
自由現金流
$91.70M+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Revenue Growth Total sales reached $2.72B USD in 2025, reflecting a strong 8.3% GAAP growth compared to the prior year.
Profitability Rebound Net income was $47.0M USD, successfully reversing the substantial $1.12B net loss recorded in 2024 operations.
Impairment Absence Zero goodwill impairment recorded in 2025 versus $1.15B goodwill and intangible asset charge recognized in 2024.
Core Sales Strength Core sales grew 6.5% USD, driven by Specialty Products segment achieving 6.3% growth for the fiscal year.
關注風險
Global Economic Volatility Global economy, inflation, and interest rates may adversely affect customer demand and utilization rates across served markets.
Trade Policy Uncertainty Trade disputes, tariffs, and protectionism increase sourcing costs and restrict market access across international operations.
Cybersecurity Incident Risk IT system breaches or ransomware attacks could seriously harm operations, cause data loss, and result in reputational damage.
Distributor Concentration Loss of key distributor Henry Schein, accounting for 12% of 2025 sales, poses a material concentration risk to revenue streams.
未來展望
Strategic Growth Investment Investing in innovation, commercialization, and clinical education remains a key priority to accelerate overall business growth trajectory.
Emerging Market Focus Continue investing in emerging markets, which represented 22% of 2025 total sales volume, expecting strong future growth driver.
Operational Efficiency Focus Utilizing Envista Business System (EBS) to improve manufacturing performance and streamline overall operational cost structure.
Recent Acquisition Integration Completed Versah acquisition for approximately $55.0M cash in February 2026 to expand portfolio with innovative dental technology.
同行對比
營業收入 (TTM)
$3.95B
$3.68B
$2.72B
毛利率 (最新季度)
89.1%
86.0%
82.1%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| CGON | $5.60B | -32.5 | -22.9% | 0.9% |
| NVST | $4.41B | 94.5 | 1.5% | 30.1% |
| ALHC | $4.25B | -5721.4 | -0.5% | 31.7% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
6.8%
穩定增長
4季度淨利複合增長率
22.3%
盈利能力大幅提升
現金流穩定性
100%
現金流表現優異
深度研究
下次財報:2026年4月29日
每股收益:-
|營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料